Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis

Eur Arch Otorhinolaryngol. 2022 Nov;279(11):5057-5069. doi: 10.1007/s00405-022-07435-2. Epub 2022 Jun 29.

Abstract

Background and purpose: Induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) has been established as standard of care for locoregionally advanced nasopharyngeal carcinoma (LANPC). No direct comparison between different IC regimens has been performed. We conducted Bayesian network meta-analysis to evaluate the efficacy and safety of IC regimens in LANPC.

Materials and methods: We systematically searched studies comparing different regimens of IC plus CCRT versus CCRT alone for LANPC. Pairwise meta-analysis and Bayesian network meta-analysis were conducted using Review Manger, Stata and R software.

Results: Eight eligible studies with a total of 2382 patients were involved. Compared with CCRT alone, IC + CCRT significantly improved PFS (HR = 0.68 [95% CI 0.59-0.79]) and OS (HR = 0.72 [95% CI 0.61-0.86]) in conventional meta-analysis. In Bayesian network meta-analysis, GP (gemcitabine and cisplatin) had advantage in prolonging PFS, OS and DMFS. GP had adverse but manageable impacts on hemoglobin and platelet. Meanwhile, treatment compliance of GP was higher than that of other regimens.

Conclusion: Based on existing evidences, GP could likely to be recommended as an optimal IC regimen for LANPC.

Keywords: Bayesian network meta-analysis; Efficacy; Induction chemotherapy; Nasopharyngeal carcinoma; Toxicity.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bayes Theorem
  • Chemoradiotherapy
  • Cisplatin / therapeutic use
  • Humans
  • Induction Chemotherapy*
  • Nasopharyngeal Carcinoma / drug therapy
  • Nasopharyngeal Carcinoma / pathology
  • Nasopharyngeal Neoplasms* / drug therapy
  • Nasopharyngeal Neoplasms* / pathology
  • Network Meta-Analysis

Substances

  • Cisplatin